Mode
Text Size
Log in / Sign up
Phase 4 N=70 Randomized Treatment

Exparel for Postoperative Pain Management in Shoulder Surgery

Fracture of Shoulder and Upper Arm

Enrolled (actual)
70
Serious AEs
1.4%
Results posted
Apr 2019
Primary outcome: Primary: Quality of Analgesia — 2.1; 2.6; 4.1; 4.0 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
1.3% Liposomal Bupivacaine (Drug); 0.125% Bupivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Wayne State University
Primary completion
May 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Quality of Analgesia
2.1; 2.6; 4.1; 4.0; 3.4; 2.6
SECONDARY
Post Operative American Shoulder and Elbow Surgeons (ASES)
36.1; 27.7; 59.5; 57.3; 74.5; 59.7
SECONDARY
Subjective Shoulder Value (SSV)
30.7; 24.3; 55.7; 63.1; 70.0; 69.3
SECONDARY
Incidence of Nerve Injury
0; 0
SECONDARY
Post Operative Opioid Consumption
78.6; 52.8

Summary

The purpose of this study is to compare the effect of liposomal Bupivacaine infiltration into the shoulder to continues nerve block with Bupivacaine on postoperative pain control and functional outcomes.

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing shoulder arthroplasty under general anesthesia
  • Patients undergoing open reduction internal fixation (ORIF) of a proximal humerus fracture under general anesthesia
  • Patients with American Society of Anesthesiologist (ASA) physical status classification of 1-3
  • Patients meeting criteria for standard of care continuous peripheral nerve block (CPNB) per anesthesia guidelines.
  • Patients agreeing to be available for brief follow up telephone survey post- operatively and being mentally able to respond.
  • Patients available for follow up routine post-operative clinic visits, per standard of care.

Exclusion Criteria

  • Contraindications to regional anesthesia
  • Significant peripheral neuropathy or neurological disorder affecting the upper extremity
  • Contraindication to a component of multimodal analgesia
  • Pregnancy
  • Opioid tolerance
  • Cognitive or psychiatric condition that might affect patient assessment and/or inability to provide informed consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02472314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search